GSK, Novartis, LEO and Lilly Boards join forces to set new patient-pharma standard
eyeforpharma, London (December, 03, 2015): C-level leaders from GSK, Novartis and Lilly have recently aligned in an effort to set out a new minimum standard or performance from their respective companies. They will announce their intentions at the eyeforpharma Barcelona Summit where a ‘new business plan’ for the industry comprising collaboration, culture and customer-centricity will be proposed.
Speaking ahead of the conference, David Epstein, CEO Pharmaceuticals, Novartis stressed a personal commitment:
“This will expand on our ‘patient declaration’ for holding the people in our company accountable, to taking a large step forward in terms of patient safety, access, transparency, and involving them in clinical trials. I am also working on changing the values of the company, being much more focused on courage, collaboration, integrity and quality, as well as performance - the very things our customers would expect of us.”
Epstein also joins leaders from LEO Pharma, ViiV Healthcare, Almirall, GSK, Eli Lilly, Janssen, Teva, Celgene and UCB on the stage – as well as patients and patient group leaders - in an unprecedented show of force, the aim being to ensure pharma companies position themselves as a vital partner in the value chain.
Over 1000 senior pharmaceutical and healthcare executives will join the CEO keynotes at the summit; taking place from 15th-17th March, 2016. For more information on the summit, to see who else will be in attendance, or to find out how this year’s agenda will influence your future business practices visit the official website, www.eyeforpharma.com/barcelona.
For more information or to arrange interviews with key speakers, contact:
Izzy Gladstone
eyeforpharma
(+44) 207 375 7519
igladstone@eyeforpharma.com